Kraig Biocraft Laboratories Announces Commencement of Full Operations at Second Production Rearing Center in Southeast Asia
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the full operational status of its second production rearing center in Southeast Asia. This expansion creates parallel operations with their existing facility, enabling continuous rearing cycles of specialized recombinant spider silk silkworms.
The new facility is working with BAM-1 production hybrids and three additional parental lines introduced in summer 2025. The dual-site strategy aims to eliminate previous production bottlenecks while increasing resilience and scalability. The expansion supports the company's commercialization strategy and strengthens their spider silk production platform.
Kraig Biocraft Laboratories (OTCQB: KBLB), una società biotecnologica specializzata nella tecnologia della seta di ragno, ha comunicato che il suo secondo centro di allevamento produttivo nel Sud-est asiatico è ora pienamente operativo. Questa espansione crea attività parallele al sito esistente, permettendo cicli continui di allevamento di bachi da seta ricombinanti specializzati.
La nuova struttura lavora con ibridi di produzione BAM-1 e tre linee parentali aggiuntive introdotte nell’estate 2025. La strategia a doppio sito punta a eliminare i colli di bottiglia produttivi precedenti aumentando nel contempo resilienza e scalabilità. L’espansione supporta la strategia di commercializzazione dell’azienda e rafforza la piattaforma di produzione della seta di ragno.
Kraig Biocraft Laboratories (OTCQB: KBLB), una empresa biotecnológica especializada en tecnología de seda de araña, ha anunciado que su segundo centro de cría productiva en el sudeste asiático está completamente operativo. Esta ampliación establece operaciones paralelas con su instalación existente, permitiendo ciclos continuos de cría de gusanos de seda recombinantes especializados.
La nueva planta trabaja con híbridos de producción BAM-1 y tres líneas parentales adicionales introducidas en el verano de 2025. La estrategia de doble emplazamiento pretende eliminar los cuellos de botella productivos anteriores, al tiempo que aumenta la resiliencia y la escalabilidad. La expansión respalda la estrategia de comercialización de la compañía y fortalece su plataforma de producción de seda de araña.
Kraig Biocraft Laboratories (OTCQB: KBLB), 거미줄(실크) 기술을 전문으로 하는 생명공학 기업이 동남아시아에 있는 두 번째 생산 사육 센터가 완전 가동 상태에 들어섰다고 발표했습니다. 이번 확장으로 기존 시설과 병행 운영이 가능해져 특수 재조합 거미 실크 누에의 연속적인 사육 주기가 실현됩니다.
새 시설은 BAM-1 생산 잡종과 2025년 여름 도입된 세 개의 추가 부모 계통을 활용하고 있습니다. 이중 사이트 전략은 기존 생산 병목을 해소하고 회복력과 확장성을 높이는 것을 목표로 합니다. 이번 확장은 회사의 상용화 전략을 지원하고 거미 실크 생산 플랫폼을 강화합니다.
Kraig Biocraft Laboratories (OTCQB: KBLB), une société de biotechnologie spécialisée dans la technologie de la soie d'araignée, a annoncé la mise en service complète de son deuxième centre d'élevage de production en Asie du Sud-Est. Cette expansion crée des opérations parallèles avec leur installation existante, permettant des cycles d'élevage continus de vers à soie recombinants spécialisés.
La nouvelle installation travaille avec des hybrides de production BAM-1 et trois lignées parentales supplémentaires introduites à l'été 2025. La stratégie à double site vise à éliminer les goulots d'étranglement de production antérieurs tout en augmentant la résilience et l'évolutivité. L'expansion soutient la stratégie de commercialisation de l'entreprise et renforce sa plateforme de production de soie d'araignée.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein Biotechnologieunternehmen, das auf Spinnenseidentechnologie spezialisiert ist, hat die vollständige Betriebsbereitschaft seines zweiten Produktionsaufzuchtzentrums in Südostasien bekanntgegeben. Diese Erweiterung schafft parallele Abläufe zum bestehenden Standort und ermöglicht kontinuierliche Aufzuchtzyklen spezieller rekombinanter Spinnenseiden-Raupen.
Die neue Anlage arbeitet mit BAM-1 Produktionshybriden und drei weiteren Elternlinien, die im Sommer 2025 eingeführt wurden. Die Zweistandortstrategie zielt darauf ab, frühere Produktionsengpässe zu beseitigen und gleichzeitig Resilienz und Skalierbarkeit zu erhöhen. Die Erweiterung unterstützt die Kommerzialisierungsstrategie des Unternehmens und stärkt seine Produktionsplattform für Spinnenseide.
- Establishment of second fully operational production facility enhances production capacity and reliability
- Integration of three new genetic lines expands breeding program capabilities
- Dual-site strategy eliminates previous production bottlenecks
- Enhanced operational redundancy improves production consistency and scalability
- Previous production bottlenecks have affected operations in the past
Parallel facilities strengthen continuous production and accelerate spider silk advancements
ANN ARBOR, Mich., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that its second production rearing center in Southeast Asia is now fully operational.
With two active production facilities, Kraig Labs has established parallel operations designed to ensure continuous rearing cycles of its specialized recombinant spider silk silkworms. This dual-site capacity increases resilience and scalability, providing greater material output consistency, as Kraig Labs advances its commercialization strategy.
Teams are now active at both rearing centers, working with the Company's established parental lines for BAM-1 production hybrids, as well as three additional parental lines introduced earlier this summer. These new genetic lines represent a significant expansion of the Company’s breeding program and are expected to further enhance production efficiencies.
These facilities are designed to create efficient redundancy to avoid bottlenecks the Company experienced in the past. This is a major leap forward in terms of creating sustained production.
"Becoming fully operational at our second rearing center is a milestone that strengthens the foundation of our spider silk production platform," said Kim Thompson, founder and CEO of Kraig Labs. "Having parallel operations allows us to maintain continuous rearing cycles, diversify our breeding program, and accelerate the development of next-generation hybrids. This expanded capacity is essential as we push forward in scaling production and bringing our recombinant spider silk to market."
The opening of this second rearing facility reflects the Company’s ongoing commitment to building a robust, reliable, and scalable spider silk production system in Southeast Asia, positioning Kraig Labs to meet growing demand from diverse markets and industries.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc. (720) 288-8495 ir@KraigLabs.com
FAQ
What is the significance of KBLB's second production facility in Southeast Asia?
How many production facilities does Kraig Biocraft Laboratories now operate in Southeast Asia?
What genetic lines is KBLB currently working with in its production facilities?
How will the new facility impact KBLB's commercialization strategy?
What challenges has KBLB faced in production previously?
